Comparison of cefiderocol in-vitro susceptibility testing modalities

Comparison of cefiderocol in-vitro susceptibility testing modalities

Bibliographic Details
Main Authors:	Nicholas S. Teran, Linh Vuong, Kady Phe, Todd M. Lasco, William R. Miller, Vincent H. Tam
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	Journal of Global Antimicrobial Resistance
Online Access:	http://www.sciencedirect.com/science/article/pii/S221371652400064X

Similar Items

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
by: Alexandre Bleibtreu, et al.
Published: (2021-01-01)

Disc Diffusion and ComASP<sup>®</sup> Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine
by: Gabriele Bianco, et al.
Published: (2023-03-01)

In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains
by: Michela Padovani, et al.
Published: (2023-04-01)

In Vitro Susceptibility of <i>Burkholderia pseudomallei</i> Isolates to Cefiderocol and Ceftazidime/Avibactam from Odisha, India
by: Jayanti Jena, et al.
Published: (2023-12-01)

Comparison of Broth Microdilution, Disk Diffusion and Strip Test Methods for Cefiderocol Antimicrobial Susceptibility Testing on KPC-Producing <i>Klebsiella pneumoniae</i>
by: Federica Bovo, et al.
Published: (2023-03-01)

Comparison of Disk Diffusion, E-Test, and Broth Microdilution Methods for Testing In Vitro Activity of Cefiderocol in <i>Acinetobacter baumannii</i>
by: Natalia Kolesnik-Goldmann, et al.
Published: (2023-07-01)

Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates
by: Clara Ballesté-Delpierre, et al.
Published: (2022-01-01)

Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France
by: Agnès B. Jousset, et al.
Published: (2023-09-01)

In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany
by: Beniam Ghebremedhin, et al.
Published: (2021-09-01)

Human Serum Proteins and Susceptibility of <i>Acinetobacter baumannii</i> to Cefiderocol: Role of Iron Transport
by: Casin Le, et al.
Published: (2022-03-01)

The Iron Content of Human Serum Albumin Modulates the Susceptibility of <i>Acinetobacter baumannii</i> to Cefiderocol
by: Jenny Escalante, et al.
Published: (2023-02-01)

Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol
by: Lana Daoud, et al.
Published: (2022-01-01)

Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol.
by: Lana Daoud, et al.
Published: (2022-01-01)

Performance of the Disc Diffusion Method, MTS Gradient Tests and Two Commercially Available Microdilution Tests for the Determination of Cefiderocol Susceptibility in <i>Acinetobacter</i> spp.
by: Katy Jeannot, et al.
Published: (2023-07-01)

In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients
by: Marguerite L. Monogue, et al.
Published: (2023-12-01)

Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it’s even arrived?
by: Chiara Russo, et al.
Published: (2024-04-01)

Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability
by: Stefano Stracquadanio, et al.
Published: (2022-10-01)

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
by: James A. Karlowsky, et al.
Published: (2022-08-01)

In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis
by: Michael M Tunney, et al.
Published: (2024-03-01)

In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17
by: Esther Wohlfarth, et al.
Published: (2023-05-01)

In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium
by: Saoussen Oueslati, et al.
Published: (2022-10-01)

In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae
by: Yu-Shan Huang, et al.
Published: (2023-06-01)

IN-VITRO ACTIVITY OF CEFIDEROCOL AGAINST CARBAPENEM-RESISTANT GRAM-NEGATIVE BACILLI: FIRST STUDY FROM INDIA
by: A. Didwania, et al.
Published: (2023-05-01)

In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA
by: Christi L. McElheny, et al.
Published: (2021-12-01)

Chelation in Antibacterial Drugs: From Nitroxoline to Cefiderocol and Beyond
by: Davorka Repac Antić, et al.
Published: (2022-08-01)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
by: Noël Zahr, et al.
Published: (2022-12-01)

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms
by: Sara Domingues, et al.
Published: (2023-06-01)

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
by: Monirul I. Sajib, et al.
Published: (2023-05-01)

Cefiderocol for prosthetic joint infection: a case report
by: MaKenzie M. Chambers, et al.
Published: (2023-05-01)

The solution to drug resistance of Gram-negative bacteria – Cefiderocol
by: Magdalena Kołodziej, et al.
Published: (2023-05-01)

Cefiderocol against Multi-Drug and Extensively Drug-Resistant <i>Escherichia coli</i>: An In Vitro Study in Poland
by: Patrycja Zalas-Więcek, et al.
Published: (2022-12-01)

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Isolates
by: Harald Seifert, et al.
Published: (2023-07-01)

Cefiderocol Protects against Cytokine- and Endotoxin-Induced Disruption of Vascular Endothelial Cell Integrity in an In Vitro Experimental Model
by: Dagmar Hildebrand, et al.
Published: (2022-04-01)

In vitro activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii clinical isolates: a single center experience.
by: Giovanni Matera
Published: (2023-06-01)

IMPROVING THE ACTIVITY OF CEFIDEROCOL BY INHIBITING Β LACTAMASES IN KLEBSIELLA PNEUMONIAE
by: L. Daoud, et al.
Published: (2023-08-01)

Proteomic Investigation of the Antibacterial Mechanism of Cefiderocol against Escherichia coli
by: Gao-Fei Du, et al.
Published: (2022-10-01)

In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex.
by: Braulio Josué Méndez-Sotelo, et al.
Published: (2024-01-01)

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
by: Stamatis Karakonstantis, et al.
Published: (2022-05-01)

Comparison of the ATB® Fungus 2 with the AFST-EUCAST for in vitro susceptibility testing of Candida spp
by: Jehidys Estella Montiel Ramos, et al.
Published: (2014-04-01)

In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
by: Davide Carcione, et al.
Published: (2021-10-01)